Medigene AG (MDG1) - Net Assets
Based on the latest financial reports, Medigene AG (MDG1) has net assets worth €19.66 Million EUR (≈ $22.98 Million USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€28.81 Million ≈ $33.68 Million USD) and total liabilities (€9.15 Million ≈ $10.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Medigene AG asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €19.66 Million |
| % of Total Assets | 68.24% |
| Annual Growth Rate | -9.19% |
| 5-Year Change | -74.25% |
| 10-Year Change | -57.07% |
| Growth Volatility | 30.45 |
Medigene AG - Net Assets Trend (2006–2023)
This chart illustrates how Medigene AG's net assets have evolved over time, based on quarterly financial data. Also explore Medigene AG total assets for the complete picture of this company's asset base.
Annual Net Assets for Medigene AG (2006–2023)
The table below shows the annual net assets of Medigene AG from 2006 to 2023. For live valuation and market cap data, see Medigene AG (MDG1) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €21.07 Million ≈ $24.63 Million |
-43.11% |
| 2022-12-31 | €37.03 Million ≈ $43.29 Million |
-17.38% |
| 2021-12-31 | €44.82 Million ≈ $52.39 Million |
-15.68% |
| 2020-12-31 | €53.15 Million ≈ $62.14 Million |
-35.04% |
| 2019-12-31 | €81.82 Million ≈ $95.66 Million |
-23.83% |
| 2018-12-31 | €107.42 Million ≈ $125.59 Million |
+24.67% |
| 2017-12-31 | €86.17 Million ≈ $100.74 Million |
+9.64% |
| 2016-12-31 | €78.59 Million ≈ $91.88 Million |
-12.66% |
| 2015-12-31 | €89.99 Million ≈ $105.21 Million |
+83.38% |
| 2014-12-31 | €49.07 Million ≈ $57.37 Million |
+35.27% |
| 2013-12-31 | €36.28 Million ≈ $42.41 Million |
-17.96% |
| 2012-12-31 | €44.22 Million ≈ $51.69 Million |
-7.75% |
| 2011-12-31 | €47.93 Million ≈ $56.04 Million |
+17.49% |
| 2010-12-31 | €40.80 Million ≈ $47.70 Million |
-21.35% |
| 2009-12-31 | €51.87 Million ≈ $60.64 Million |
-20.08% |
| 2008-12-31 | €64.91 Million ≈ $75.88 Million |
-37.04% |
| 2007-12-31 | €103.09 Million ≈ $120.53 Million |
-4.99% |
| 2006-12-31 | €108.51 Million ≈ $126.86 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medigene AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47929900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €24.56 Million | 116.60% |
| Other Comprehensive Income | €2.45 Million | 11.62% |
| Other Components | €480.25 Million | 2279.72% |
| Total Equity | €21.07 Million | 100.00% |
Medigene AG Competitors by Market Cap
The table below lists competitors of Medigene AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PALATIN TECHS DL-01
F:PTN
|
$1.97 Million |
|
Maschinenfabrik HEID AG
VI:HED
|
$1.97 Million |
|
Accsys Technologies PLC
LSE:AXS
|
$1.97 Million |
|
Diadrom Holding AB
ST:DIAH
|
$1.97 Million |
|
Leapfrog Acquisition Corporation Warrants
NASDAQ:LFACW
|
$1.97 Million |
|
NO GRAVITY GAMES ZY -10
F:8YX
|
$1.97 Million |
|
Phoenix Spree Deutschland Ltd
LSE:PSDL
|
$1.96 Million |
|
Body One SA
PA:MLONE
|
$1.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medigene AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 37,027,000 to 21,066,000, a change of -15,961,000 (-43.1%).
- Net loss of 16,177,000 reduced equity.
- Other comprehensive income decreased equity by 92,000.
- Other factors increased equity by 308,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-16.18 Million | -76.79% |
| Other Comprehensive Income | €-92.00K | -0.44% |
| Other Changes | €308.00K | +1.46% |
| Total Change | €- | -43.11% |
Book Value vs Market Value Analysis
This analysis compares Medigene AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.16x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.01x to 0.16x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | €15.15 | €0.13 | x |
| 2007-12-31 | €13.07 | €0.13 | x |
| 2008-12-31 | €7.63 | €0.13 | x |
| 2009-12-31 | €6.06 | €0.13 | x |
| 2010-12-31 | €4.44 | €0.13 | x |
| 2011-12-31 | €5.15 | €0.13 | x |
| 2012-12-31 | €4.73 | €0.13 | x |
| 2013-12-31 | €3.77 | €0.13 | x |
| 2014-12-31 | €4.02 | €0.13 | x |
| 2015-12-31 | €5.35 | €0.13 | x |
| 2016-12-31 | €3.94 | €0.13 | x |
| 2017-12-31 | €4.01 | €0.13 | x |
| 2018-12-31 | €4.54 | €0.13 | x |
| 2019-12-31 | €3.33 | €0.13 | x |
| 2020-12-31 | €2.16 | €0.13 | x |
| 2021-12-31 | €1.82 | €0.13 | x |
| 2022-12-31 | €1.51 | €0.13 | x |
| 2023-12-31 | €0.81 | €0.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medigene AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -76.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -268.10%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.51x
- Recent ROE (-76.79%) is below the historical average (-26.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -6.35% | -22.07% | 0.25x | 1.14x | €-17.74 Million |
| 2007 | -28.98% | -125.12% | 0.21x | 1.11x | €-40.19 Million |
| 2008 | -47.44% | -77.74% | 0.49x | 1.24x | €-37.28 Million |
| 2009 | -42.34% | -55.65% | 0.60x | 1.27x | €-27.15 Million |
| 2010 | -43.80% | -779.62% | 0.04x | 1.43x | €-21.95 Million |
| 2011 | 13.10% | 134.90% | 0.09x | 1.11x | €1.49 Million |
| 2012 | -22.30% | -156.89% | 0.10x | 1.39x | €-14.28 Million |
| 2013 | -28.34% | -135.43% | 0.14x | 1.45x | €-13.91 Million |
| 2014 | -11.73% | -41.77% | 0.19x | 1.45x | €-10.66 Million |
| 2015 | -14.45% | -190.94% | 0.06x | 1.26x | €-22.00 Million |
| 2016 | -12.08% | -97.36% | 0.09x | 1.42x | €-17.35 Million |
| 2017 | -15.75% | -119.32% | 0.10x | 1.30x | €-22.19 Million |
| 2018 | -15.87% | -219.87% | 0.06x | 1.21x | €-27.79 Million |
| 2019 | -24.40% | -187.75% | 0.10x | 1.33x | €-28.14 Million |
| 2020 | -54.32% | -330.04% | 0.12x | 1.41x | €-34.19 Million |
| 2021 | -22.28% | -95.41% | 0.18x | 1.33x | €-14.46 Million |
| 2022 | -22.50% | -26.66% | 0.60x | 1.40x | €-12.03 Million |
| 2023 | -76.79% | -268.10% | 0.19x | 1.51x | €-18.28 Million |
Industry Comparison
This section compares Medigene AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $555,085,471
- Average return on equity (ROE) among peers: -68.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medigene AG (MDG1) | €19.66 Million | -6.35% | 0.47x | $1.97 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $115.18 Million | -247.79% | 2.83x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-5.78 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $209.51 Million | -46.30% | 0.68x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $-48.21 Million | 0.00% | 0.00x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.54 Billion | -12.40% | 0.05x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.83 Billion | 9.08% | 0.22x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About Medigene AG
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more